Foekens J A, Henkelman M S, Fukkink J F, Blankenstein M A, Klijn J G
Biochem Biophys Res Commun. 1986 Oct 30;140(2):550-6. doi: 10.1016/0006-291x(86)90767-9.
The growth-stimulation of MCF-7 human breast cancer cells in vitro induced by 30 pM estradiol was inhibited both by the LHRH-agonist Buserelin and the anti-estrogen Tamoxifen used as single agents. Combined administration of both drugs was less effective in this respect. In the presence of estradiol Buserelin had no effect on the pattern of [35S]methionine labelled secretory proteins when examined with one-dimensional gel electrophoresis, whereas the estrogen-induced progesterone receptor synthesis was inhibited. Thus with estradiol concentrations comparable to plasma values in medically castrated patients, the LHRH-agonist Buserelin can directly inhibit breast cancer cell growth in vitro.
